Earnings Call Excerpt
Genomic Health, Inc. (GHDX)
Q2 2009 Earnings Call Transcript
August 4, 2009 4:30 pm ET
Executives
Dean Schorno - VP, Finance
Kim Popovits - President and CEO
Brad Cole - COO and CFO
Steve Shak - Chief Medical Officer
Analysts
David Clair - Piper Jaffray
Peter Lawson - Thomas Weisel Partners
Charles Duncan - JMP Securities
Scott Gleason - Stephens Inc.
Ashim Anand - Natixis Bleichroeder
Abigail Davis [ph] - JPMorgan
Matthew Scalo - Canaccord Adams
Kelley Roche - Leerink Swann
Presentation
Operator
Good afternoon. My name is Kairy and I will be your conference operator today. At this time, I would like to welcome everyone to the Genomic Health second quarter 2009 financial results conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. (Operator instructions)
I would now like to turn the conference over to Mr. Dean Schorno, Vice President of Finance. Sir, you may begin your conference.
Dean Schorno
Thank you. Good afternoon everyone and welcome to Genomic Health’s second quarter 2009 financial results conference call.
Before we begin, I would like to remind you that various remarks we make on this call that are not historical, including those about our future financial operating results, future plans and prospects, the success of our business strategy, the impact of clinical data on demand for our tests, economic benefits and value to payers of our tests, growth and market opportunities, future products, product enhancements and our product pipeline, demand for our test and drivers of demand, payer coverage and pricing, progress in patient access, our investment in our product pipeline and commercial organization, clinical outcomes and timing of clinical studies, our plans for international expansion, the impact of the economy in our business, and our expectations regarding our ability to comply with potential FDA regulation, constitute forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act.
We refer you to our annual report on Form 10-Q for the quarter ended March 31, 2009 filed with the SEC, in particular to the section entitled, Risk Factors, for additional information on factors that could cause actual results to differ materially from our current expectations. These forward-looking statements speak only as of the date hereof and we disclaim any obligation to update these forward-looking statements.
With that, I’ll turn the call over to Kim Popovits, President and CEO of Genomic Health.
- To read the full transcript on Seeking Alpha, click here »
